Skip to main content

Table 2 General clinical data of two groups of patients

From: Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis

Group

Group A (n=34)

Group B (n=34)

P

Age (years)

 ≤61.00

5(14.71)

3(8.82)

0.452

 >61.00

29(85.29)

31(91.18)

 

 Weight (kg)

58.90±8.15

57.70±9.00

0.566

Residence

 Rural

26(76.47)

23(67.65)

0.418

 Urban

8(23.53)

11(32.35)

Family history of epithelial ovarian cancer

 Yes

0(0.00)

4(11.76)

0.039

 No

34(100.00)

30(88.24)

Smoking history

 Yes

32(94.12)

30(88.24)

0.393

 No

2(5.88)

4(11.76)

Differentiation

 High

0(0.00)

0(0.00)

0.604

 Medium

10(29.41)

12(35.29)

 Low

24(70.59)

22(64.51)

Lymph node metastasis

 Yes

18(52.94)

19(55.88)

0.808

 No

16(47.06)

15(44.12)

Stage of epithelial ovarian cancer

 II

4(11.76)

3(8.82)

0.916

 III

15(44.12)

16(47.06)

 IV

15(44.12)

15(44.12)